KROS Q4 2024 Earnings — Keros Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KROSKeros Therapeutics, Inc.

$414M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+2027.3% YoY

Gross Profit

$3M89.1% margin

Operating Income

-$53M-1750.6% margin

Net Income

-$46M-1513.0% margin

EPS (Diluted)

$-1.14

QoQ Revenue Growth

+684.0%

Cash Flow

Operating Cash Flow

-$46M

Free Cash Flow

-$46M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$616M

Total Liabilities

$44M

Stockholders' Equity

$572M

Cash & Equivalents

$560M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$143,000	+2027.3%
Gross Profit	$3M	$143,000	+1795.1%
Operating Income	-$53M	-$46M	-14.6%
Net Income	-$46M	-$40M	-14.4%

Revenue Segments

Service

$3M100%